1. Home
  2. NPKI vs COAG Comparison

NPKI vs COAG Comparison

Compare NPKI & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NPK International Inc.

NPKI

NPK International Inc.

HOLD

Current Price

$14.27

Market Cap

1.2B

Sector

Industrials

ML Signal

HOLD

Logo Hemab Therapeutics Holdings Inc. Common Stock

COAG

Hemab Therapeutics Holdings Inc. Common Stock

N/A

Current Price

$31.13

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NPKI
COAG
Founded
1932
N/A
Country
United States
United States
Employees
510
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.4B
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
NPKI
COAG
Price
$14.27
$31.13
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$14.17
N/A
AVG Volume (30 Days)
1.2M
252.9K
Earning Date
04-30-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.39
N/A
Revenue Next Year
$11.70
N/A
P/E Ratio
$38.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.17
$27.47
52 Week High
$16.50
$38.87

Technical Indicators

Market Signals
Indicator
NPKI
COAG
Relative Strength Index (RSI) 42.67 48.05
Support Level $13.70 $27.47
Resistance Level $15.28 $38.87
Average True Range (ATR) 0.77 3.96
MACD -0.06 0.21
Stochastic Oscillator 13.16 30.96

Price Performance

Historical Comparison
NPKI
COAG

About NPKI NPK International Inc.

NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. It generates maximum revenue from United States.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: